Bright Minds Biosciences Inc (DRUG) Stock Price, Quote & News

Company Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indicatio...

Industry: Biotechnology

Sector: Healthcare

Phone: 647 865 8622

Website: brightmindsbio.com

Address:

19 Vestry Street, New York, United States

TimeTRAVELER101 Dec. 24 at 11:31 PM

$DRUG 4x and losing money huh……

0 · Reply

IVALTE Dec. 23 at 6:42 PM

$MBRX next $DRUG

0 · Reply

VegasG Dec. 23 at 5:21 PM

$DRUG HOW MANY OF YOU BRILLIANT OR LUCKY MOFOS TOLD THE BOSS “LATER DUDE!!! I don’t WORK any more!”😎🤣🤣🤣🤣🤣🤣🤣🤣🤣MERRY MERRY XMAS

1 · Reply

Thralling Dec. 23 at 4:26 PM

$MGRX well if it does RS and then doubles. I am good with that. Look at $DRUG they had a hard time getting going.

0 · Reply

Parabolicsuperman Dec. 22 at 12:28 PM

$CMCT I was in $DRUG before the short squeeze, I am getting the same feeling here

0 · Reply

S2K_TP Dec. 22 at 1:38 AM

🚨 Major Monday's earnings releases after bell: $ANGH after bell $MAXN after bell $DRUG after bell $ATON after bell $ALTS after bell

4 · Reply

Thralling Dec. 20 at 8:22 AM

$MGRX reminds me of $DRUG they struggled also.

0 · Reply

CocaKolla Dec. 19 at 7:37 PM

$NBY we have next $DRUG ??

0 · Reply

twib Dec. 19 at 5:27 PM

$DRUG Been killing it over last 6mo!👍

0 · Reply

PROJECTEDSQUEEZES Dec. 18 at 7:35 PM

$DRUG Hey everyone! Could. INM be the next Drug. Take a look and tell me what you think!

0 · Reply

Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting

Nov 17, 2025, 6:50 AM EST - 5 weeks ago

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

Nov 6, 2025, 6:30 AM EST - 6 weeks ago

Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

May 20, 2025, 8:00 AM EDT - 7 months ago

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

May 7, 2025, 4:45 PM EDT - 8 months ago

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

Apr 28, 2025, 8:00 AM EDT - 8 months ago

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Apr 16, 2025, 12:09 PM EDT - 9 months ago

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Jan 26, 2025, 6:32 AM EST - 11 months ago

Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

Jan 7, 2025, 6:50 AM EST - 1 year ago

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Nov 4, 2024, 2:41 PM EST - 1 year ago

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Oct 30, 2024, 1:07 AM EDT - 1 year ago

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

NVCT

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Oct 18, 2024, 6:50 AM EDT - 1 year ago

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Oct 16, 2024, 10:45 AM EDT - 1 year ago

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Oct 15, 2024, 9:09 PM EDT - 1 year ago

Bright Minds is Unaware of Any Material Changes

Oct 3, 2024, 9:00 AM EDT - 1 year ago

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Sep 19, 2024, 10:00 AM EDT - 1 year ago

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Aug 8, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 20, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 12, 2023, 10:33 AM EDT - 2 years ago

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Jul 11, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Effective Date of Share Consolidation

Jun 22, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Proposed Share Consolidation

Apr 19, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Apr 10, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Feb 27, 2023, 6:50 AM EST - 3 years ago

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Feb 17, 2023, 6:50 AM EST - 3 years ago

Bright Minds Biosciences Announces Non-Executive Director Appointment

Feb 8, 2023, 4:05 PM EST - 3 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Jan 27, 2023, 4:05 PM EST - 3 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Jan 9, 2023, 4:05 PM EST - 3 years ago

Bright Minds Biosciences Announces Resignation of Board Member

Dec 2, 2022, 7:07 PM EST - 3 years ago

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Nov 28, 2022, 6:50 AM EST - 3 years ago

Bright Minds Biosciences Announces Non-Brokered Private Placement

Nov 23, 2022, 11:35 AM EST - 3 years ago

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.

Sep 7, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Aug 31, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Aug 30, 2022, 3:35 PM EDT - 3 years ago

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Aug 23, 2022, 9:07 PM EDT - 3 years ago

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

Aug 22, 2022, 7:05 PM EDT - 3 years ago

Bright Minds Announces Overnight Marketed Offering of Units

Aug 18, 2022, 3:34 PM EDT - 3 years ago

Bright Minds Biosciences Comments on Recent Trading Activity

Jun 27, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

May 12, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

May 2, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Nov 30, 2021, 7:30 AM EST - 4 years ago

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Nov 4, 2021, 8:52 AM EDT - 4 years ago

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Nov 3, 2021, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

TimeTRAVELER101 Dec. 24 at 11:31 PM

$DRUG 4x and losing money huh……

0 · Reply

IVALTE Dec. 23 at 6:42 PM

$MBRX next $DRUG

0 · Reply

VegasG Dec. 23 at 5:21 PM

$DRUG HOW MANY OF YOU BRILLIANT OR LUCKY MOFOS TOLD THE BOSS “LATER DUDE!!! I don’t WORK any more!”😎🤣🤣🤣🤣🤣🤣🤣🤣🤣MERRY MERRY XMAS

1 · Reply

Thralling Dec. 23 at 4:26 PM

$MGRX well if it does RS and then doubles. I am good with that. Look at $DRUG they had a hard time getting going.

0 · Reply

Parabolicsuperman Dec. 22 at 12:28 PM

$CMCT I was in $DRUG before the short squeeze, I am getting the same feeling here

0 · Reply

S2K_TP Dec. 22 at 1:38 AM

🚨 Major Monday's earnings releases after bell: $ANGH after bell $MAXN after bell $DRUG after bell $ATON after bell $ALTS after bell

4 · Reply

Thralling Dec. 20 at 8:22 AM

$MGRX reminds me of $DRUG they struggled also.

0 · Reply

CocaKolla Dec. 19 at 7:37 PM

$NBY we have next $DRUG ??

0 · Reply

twib Dec. 19 at 5:27 PM

$DRUG Been killing it over last 6mo!👍

0 · Reply

PROJECTEDSQUEEZES Dec. 18 at 7:35 PM

$DRUG Hey everyone! Could. INM be the next Drug. Take a look and tell me what you think!

0 · Reply

Benbobaggins Dec. 16 at 9:44 PM

$BEAT This has exponential gains written all over it from the ticker name to the way its going up and also the product itself being for the people and not just a random meme stock based purely on hype. I was upset when i had $DRUG 2000 shares at $3 and then it went up the day after i sold it at $11 to 60/70 and then again with $SMX when it was $11 dollars at 250 shares and then i sold it and then it went up to 270s and then 400s. I have that feeling now and no matter what not selling until the end 🙏🏼❤️

2 · Reply

www_larval_com Dec. 16 at 8:52 PM

$TGL 6%[-2%] $BEAT -5%[29%] $NBP -3%[3%] $DTCX 3%[-7%] $DRUG -3%[9%] most notable movement into the final minutes of trading.

0 · Reply

MrEsKurr Dec. 16 at 8:46 PM

$DRUG In for ER hype. got in at closing prices here.

1 · Reply

Lucky72 Dec. 16 at 8:12 PM

$DRUG Ya Dig ? AYTU ✅

0 · Reply

Lucky72 Dec. 16 at 7:51 PM

$DRUG AYTU is another one.Do you’re due diligence.Ground floor opportunity.IMO

0 · Reply

Doozio Dec. 16 at 7:04 PM

$DRUG faaatch 💣 or……

0 · Reply

lachanceKdance Dec. 16 at 5:11 PM

$DRUG always believed drug is the answer

0 · Reply

LowFloatOnly Dec. 15 at 9:08 PM

$QH 900k Float, insane squeeze setup with crazy short% past days SKYROCKETED! Could pull that $DRUG $BYND $GME move if you ask me!!

0 · Reply

LowFloatOnly Dec. 15 at 6:07 PM

$SUGP Soon out of the long term woods 🌳 reminds me of that $5 bottom on $CVNA $DRUG

0 · Reply

___dog___ Dec. 15 at 3:37 PM

$DRUG ahhhhh drugs

0 · Reply

honestrick Dec. 14 at 1:43 AM

$XRTX Webinar for $XRTX on Jan21,2026 at 4.15 pm is a good sign. Jan is usually the start of good things for a stock . Looking for a move up and a continue after the webinar .$DRUG $CGC $BB

0 · Reply

BioTechHealthX Dec. 13 at 11:21 PM

$DRUG Bright Minds Biosciences (NASDAQ:DRUG) is developing targeted CNS therapies designed to treat epilepsy and neuropsychiatric disorders with improved safety. This in-depth report explains the science, pipeline focus, and why investors are paying attention. https://biotechhealthx.com/biotech-news/bright-minds-biosciences-drug-the-precision-neuroscience-stock-wall-street-is-watching/

0 · Reply

Market Cap	656.11M
Revenue (ttm)	0.00
Net Income (ttm)	-2.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	117,900
Avg Vol	170,932
Day's Range	N/A - N/A
Shares Out	7.79M
Stochastic %K	34%
Beta	-6.22
Analysts	Strong Sell
Price Target	$82.40